|
End-of-day quote
Other stock markets
|
5-day change | 1st Jan Change | ||
| 17.23 CNY | +0.70% |
|
-1.82% | -7.27% |
| Jan. 16 | Shenzhen Chipscreen Biosciences Gets Acceptance for Patent Invalidation Request | MT |
| Nov. 28 | Shenzhen Chipscreen Biosciences Gets China Approval for Tumor Medication | MT |
| Capitalization | 7.03B 970M 924M 879M 777M 1.39B 83.56B 1.54B 10.6B 3.89B 34.6B 3.63B 3.56B 151B | P/E ratio 2024 * |
-82x | P/E ratio 2025 * | -101x |
|---|---|---|---|---|---|
| Enterprise value | 7.03B 970M 924M 879M 777M 1.39B 83.56B 1.54B 10.6B 3.89B 34.6B 3.63B 3.56B 151B | EV / Sales 2024 * |
9.95x | EV / Sales 2025 * | 7.09x |
| Free-Float |
61.11% | Yield 2024 * |
-
| Yield 2025 * | - |
More valuation ratios
* Estimated data
More news
More press releases
| 1 day | +0.70% | ||
| 1 week | -1.82% | ||
| Current month | -7.27% | ||
| 1 month | -11.91% | ||
| 3 months | -26.02% | ||
| 6 months | +4.81% | ||
| Current year | -7.27% |
1 week
16.85
17.97
1 month
16.5219.55
Current year
16.5218.69
1 year
12.4725.99
3 years
12.4732.39
5 years
12.4782.89
10 years
12.47125.00
| Director | Title | Age | Since |
|---|---|---|---|
Zhi Qiang Ning
CTO | Chief Tech/Sci/R&D Officer | 65 | 2001-04-30 |
Xian Ping Lu
CEO | Chief Executive Officer | 62 | 2018-03-23 |
Jian Xun Li
DFI | Director of Finance/CFO | 54 | 2001-05-31 |
| Manager | Title | Age | Since |
|---|---|---|---|
Xian Ping Lu
CHM | Chairman | 62 | 2018-03-23 |
Jian Xun Li
BRD | Director/Board Member | 54 | 2018-03-23 |
Ou Hai
BRD | Director/Board Member | 47 | 2018-03-23 |
| Change | 5d. change | 1-year change | 3-years change | Capi. ($) | ||
|---|---|---|---|---|---|---|
| +0.70% | -1.82% | -2.93% | -49.29% | 970M | ||
| +0.45% | +2.62% | -1.23% | -23.66% | 66.31B | ||
| +0.96% | +1.27% | -2.63% | -21.59% | 7.57B | ||
| +0.25% | +1.77% | +59.12% | +60.72% | 7.1B | ||
| +1.56% | -3.06% | +118.32% | +142.74% | 6.81B | ||
| +0.46% | -0.46% | +21.33% | +31.41% | 5.99B | ||
| +1.53% | +0.84% | +35.53% | -20.03% | 3.26B | ||
| +0.95% | +1.39% | +33.03% | +25.70% | 2.15B | ||
| -0.23% | +2.15% | +37.34% | +32.29% | 2.13B | ||
| +0.48% | +0.93% | -33.58% | +21.32% | 1.71B | ||
| Average | +0.71% | +0.46% | +26.43% | +19.96% | 10.4B | |
| Weighted average by Cap. | +0.58% | +1.87% | +14.02% | -0.90% |
| 2024 * | 2025 * | |
|---|---|---|
| Net sales | 706M 97.47M 92.89M 88.31M 78.09M 140M 8.4B 154M 1.07B 391M 3.48B 365M 358M 15.2B | 991M 137M 130M 124M 110M 196M 11.79B 217M 1.5B 549M 4.88B 513M 502M 21.33B |
| Net income | -84M -11.6M -11.05M -10.51M -9.29M -16.64M -999M -18.38M -127M -46.55M -414M -43.45M -42.59M -1.81B | -68M -9.39M -8.95M -8.51M -7.52M -13.47M -809M -14.88M -103M -37.68M -335M -35.17M -34.48M -1.46B |
| Net Debt | - | - |
More financial data
* Estimated data
Employees
1,057
Sector
Pharmaceuticals
Calendar
2025-04-24
- Q1 2025 Earnings Release (Projected)
| Date | Price | Change | Volume |
|---|---|---|---|
| 25-01-24 | 17.23 ¥ | +0.70% | 2,971,460 |
| 25-01-23 | 17.11 ¥ | +0.35% | 3,351,734 |
| 25-01-22 | 17.05 ¥ | -0.87% | 2,599,447 |
| 25-01-21 | 17.20 ¥ | -1.88% | 3,752,466 |
| 25-01-20 | 17.53 ¥ | -0.11% | 3,447,269 |
End-of-day quote Shanghai S.E., January 23, 2025
More quotes
Sell
Buy
Mean consensus
BUY
Number of Analysts
1
Last Close Price
17.23CNY
Average target price
37.60CNY
Spread / Average Target
+118.22%
Annual profits - Rate of surprise
- Stock Market
- Equities
- 688321 Stock